Taro Pharmaceutical Industries Ltd.  

(Public, NYSE:TARO)   Watch this stock  
Find more results for Taro Pharmaceutical Industries Ltd
+0.51 (0.46%)
Apr 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 109.24 - 110.37
52 week 53.56 - 122.51
Open 110.00
Vol / Avg. 24,063.00/43,944.00
Mkt cap 4.94B
P/E 15.36
Div/yield     -
EPS 7.18
Shares 44.77M
Beta 0.36
Inst. own 10%
May 19, 2014
Q4 2014 Taro Pharmaceutical Industries Ltd Earnings Release (Estimated) Add to calendar
Mar 27, 2014
Taro Pharmaceutical Industries Ltd Extraordinary Shareholder Meeting
Feb 10, 2014
Q3 2014 Taro Pharmaceutical Industries Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 54.20% 39.95%
Operating margin 63.15% 48.97%
EBITD margin - 56.58%
Return on average assets 37.19% 27.31%
Return on average equity 46.82% 35.53%
Employees 1,294 -
CDP Score - -


14 Hakitor Street, Haifa Bay P.O. Box 10347
HAIFA, 26110
+972-4-8475700 (Phone)
+972-4-8727165 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Taro Pharmaceutical Industries Ltd. is a science-based pharmaceutical company. The Company develops manufactures, and markets prescription and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. The Company also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company�s primary areas of focus include pediatric creams and ointments, liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company operates through three companies: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries (including indirect), Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets more than 180 pharmaceutical products in over 25 countries.

Officers and directors

Dilip Shantilal Shanghvi Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Kalyanasundaram Subramanian Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Michael H. Kalb CPA Interim Chief Financial Officer, Group Vice President, Chief Accounting Officer; Chief Financial Officer of Taro U.S.A.
Age: 42
Bio & Compensation  - Reuters
Stephen Manzano Esq. Interim General Counsel, Vice President of Corporate Compliance
Age: 48
Bio & Compensation  - Reuters
Sunil Mehta Group Vice President, General Manager - Canadian operations
Age: 53
Bio & Compensation  - Reuters
Brant Schofield Vice President - Sales & Marketing, TPHA, U.S.A.
Age: 47
Bio & Compensation  - Reuters
Michele Visosky Vice President - Human Resources, U.S.A.
Age: 47
Bio & Compensation  - Reuters
Mariana Bacalu Group Vice President - Quality Affairs
Age: 61
Bio & Compensation  - Reuters
Michael Teiler Group Vice President - Portfolio Management
Age: 50
Bio & Compensation  - Reuters
Rami Zajicek Esq. Group Vice President, Haifa Site Manager
Age: 49
Bio & Compensation  - Reuters